Complex pathogens in infective endocarditis

Abstract

Infective endocarditis (IE) is a complex disease whose prognosis depends on the causative microorganism, among other factors. The latter can be difficult to identify and/or treat. In this narrative review, we identify knowledge gaps in the diagnosis and antimicrobial treatment of IE, and attempt to shed light on current questions. Specifically, we: (1) analyze the factors that may hinder the microbiological diagnosis of blood culture-negative IE, as well as the role of new imaging techniques, such as ¹⁸F-fluorodeoxyglucose ([¹⁸F]FDG PET/CT), in the diagnostic capacity of this disease, understanding their advantages and assuming their limitations; (2) discuss the therapeutic approach to various difficult-to-treat microorganisms. In particular, we focus on the treatment of staphylococcal IE since, at present, staphylococci are the most frequent cause of IE in developed countries and staphylococcal IE is one of those with the highest short- and long-term mortality. We critically evaluate the current evidence on combination therapy and address the occurrence of serious side effects, an aspect that is often overlooked owing to the severity of the infection; and (3) emphasize the need for home antimicrobial treatment of patients with IE, as these are fragile people who benefit from an early return to their environment. This poses undoubted logistical challenges and requires robust evidence to ensure the best short- and long-term outcomes.

Keywords

Endocarditis / diagnosis / treatment / blood culture-negative infective endocarditis / outpatient / PET/CT / difficult to treat

References

[1] Osler W.The gulstonian lectures, on malignant endocarditis.Br Med J1885;1:467-70

[2] Osler W.The gulstonian lectures, on malignant endocarditis.Br Med J1885;1:522-6

[3] Osler W.The gulstonian lectures, on malignant endocarditis.Br Med J1885;1:577-9 PMCID:PMC2255919

[4] Varela Barca L,Fariñas MC.Analysis of sex differences in the clinical presentation, management and prognosis of infective endocarditis in Spain.Heart2021;107:1717-24

[5] Baddour LM,Lahr BD.A contemporary population-based profile of infective endocarditis using the expanded rochester epidemiology project.Mayo Clin Proc2021;96:1438-45 PMCID:PMC8180504

[6] Naidoo NS,Naidoo DP.A 10-year retrospective analysis of the clinical profile and outcomes of infective endocarditis at a tertiary hospital in KwaZulu-Natal, South Africa.Cardiovasc J Afr2022;33:194-9 PMCID:PMC9650145

[7] Nienaber CA,Sakalihasan N.Aortic dissection.Nat Rev Dis Primers2016;2:16053

[8] Fernández-Hidalgo N,Tornos P.Immediate and long-term outcome of left-sided infective endocarditis. a 12-year prospective study from a contemporary cohort in a referral hospital.Clin Microbiol Infect2012;18:E522-30

[9] Murdoch DR,Hoen B.Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.Arch Intern Med2009;169:463-73 PMCID:PMC3625651

[10] Fernández-Hidalgo N,Larrosa MN.Impact of staphylococcus aureus phenotype and genotype on the clinical characteristics and outcome of infective endocarditis. a multicentre, longitudinal, prospective, observational study.Clin Microbiol Infect2018;24:985-91

[11] Escolà-Vergé L,Larrosa MN,Almirante B.Secular trends in the epidemiology and clinical characteristics of Enterococcus faecalis infective endocarditis at a referral center (2007-2018).Eur J Clin Microbiol Infect Dis2021;40:1137-48

[12] Fernández-Hidalgo N,Tornos P.Prognosis of left-sided infective endocarditis in patients transferred to a tertiary-care hospital-prospective analysis of referral bias and influence of inadequate antimicrobial treatment.Clin Microbiol Infect2011;17:769-75

[13] Botelho-Nevers E,Casalta JP.Dramatic reduction in infective endocarditis-related mortality with a management-based approach.Arch Intern Med2009;169:1290-8

[14] Cambridge dictionary. Available from: https://dictionary.cambridge.org [Last accessed on 25 May 2023]

[15] Tattevin P,Revest M,Fournier PE.Update on blood culture-negative endocarditis.Med Mal Infect2015;45:1-8

[16] Ferrera C,Fernández C.Reassessment of blood culture-negative endocarditis: its profile is similar to that of blood culture-positive endocarditis.Rev Esp Cardiol2012;65:891-900

[17] Lamas CC,Zappa M.Diagnosis of blood culture-negative endocarditis and clinical comparison between blood culture-negative and blood culture-positive cases.Infection2016;44:459-66

[18] Díez-Villanueva P,Marín M.Infective endocarditis: absence of microbiological diagnosis is an independent predictor of inhospital mortality.Int J Cardiol2016;220:162-5

[19] Firiana L,Yonas E,Pranata R.Factors affecting mortality in patients with blood-culture negative infective endocarditis.Int J Angiol2020;29:12-8 PMCID:PMC7054058

[20] Suardi LR,García MV.Blood culture-negative infective endocarditis: a worse outcome?.Infect Dis2021;53:755-63

[21] Habib G,Antunes MJ.2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the european society of cardiology (ESC). endorsed by: european association for cardio-thoracic surgery (EACTS), the european association of nuclear medicine (EANM).Eur Heart J2015;36:3075-128

[22] Pecoraro AJK,Herbst PG.Causes of infective endocarditis in the Western Cape, South Africa: a prospective cohort study using a set protocol for organism detection and central decision making by an endocarditis team.BMJ Open2021;11:e053169 PMCID:PMC8650472

[23] Saby L,Habib G.Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular ¹⁸F-fluorodeoxyglucose uptake as a novel major criterion.J Am Coll Cardiol2013;61:2374-82

[24] Pizzi MN,Fernández-Hidalgo N.Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with ¹⁸F-fluordeoxyglucose positron emission tomography/computed tomography angiography.Circulation2015;132:1113-26

[25] Sarrazin JF,Tessier M.Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections.J Am Coll Cardiol2012;59:1616-25

[26] Graziosi M,Lorenzini M.Role of ¹⁸F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study.Eur J Nucl Med Mol Imaging2014;41:1617-23

[27] Otto CM,Bonow RO.2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.Circulation2021;143:e72-e227

[28] Blomström-Lundqvist C,Erba PA.European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).Eur Heart J2020;41:2012-32

[29] Wang TKM,Igbinomwanhia E,Griffin B.Diagnosis of infective endocarditis by subtype using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography: a contemporary meta-analysis.Circ Cardiovasc Imaging2020;13:e010600

[30] Juneau D,Hazra S.Positron emission tomography and single-photon emission computed tomography imaging in the diagnosis of cardiac implantable electronic device infection: a systematic review and meta-analysis.Circ Cardiovasc Imaging2017;10:e005772

[31] Scholtens AM,Budde RP.Effect of antibiotics on FDG-PET/CT imaging of prosthetic heart valve endocarditis.Eur Heart J Cardiovasc Imaging2015;16:1223

[32] Auletta S,Horvat R,Signore A.PET radiopharmaceuticals for specific bacteria imaging: a systematic review.J Clin Med2019;8:197 PMCID:PMC6406348

[33] Cuervo G,Gudiol C.Current challenges in the management of infective endocarditis.Front Med2021;8:641243 PMCID:PMC7937698

[34] Selton-Suty C,Le Moing V.Preeminence of staphylococcus aureus in infective endocarditis: a 1-year population-based survey.Clin Infect Dis2012;54:1230-9

[35] Habib G,Iung B.Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study.Eur Heart J2019;40:3222-32

[36] Tissot-Dupont H,Gouriet F.International experts’ practice in the antibiotic therapy of infective endocarditis is not following the guidelines.Clin Microbiol Infect2017;23:736-9

[37] García de la Mària C,Pericàs JM.Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.PLoS One2015;10:e0125818 PMCID:PMC4427314

[38] Holmes NE,Munckhof WJ.Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.J Infect Dis2011;204:340-7

[39] Aguado JM,Lalueza A.High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia.Emerg Infect Dis2011;17:1099-102 PMCID:PMC3358192

[40] Lebeaux D,Pilmis B,Mainardi JL.Aminoglycosides for infective endocarditis: time to say goodbye?.Clin Microbiol Infect2020;26:723-8

[41] Thwaites GE,Szubert A.Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.Lancet2018;391:668-78

[42] Shrestha NK,Wang H.Rifampin for surgically treated staphylococcal infective endocarditis: a propensity score-adjusted cohort study.Ann Thorac Surg2016;101:2243-50

[43] Le Bot A,Gazeau P.Is rifampin use associated with better outcome in staphylococcal prosthetic valve endocarditis?.Clin Infect Dis2021;72:e249-55

[44] Cheng MP,Butler-Laporte G,Paquette K.Adjunctive daptomycin in the treatment of methicillin-susceptible staphylococcus aureus Bacteremia: a randomized, controlled trial.Clin Infect Dis2021;72:e196-203

[45] Pujol M,Shaw E.Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial.Clin Infect Dis2021;72:1517-25

[46] Tong SYC,Yahav D.Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial.JAMA2020;323:527-37

[47] Tattevin P,Vitrat V.Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study.J Antimicrob Chemother2014;69:2010-3

[48] Destache CJ,Kaye KS.Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience.Int J Antimicrob Agents2019;53:644-9

[49] Pericàs JM,Almela M.Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial.Clin Microbiol Infect2018;24:673-6

[50] Lecomte R,Deschanvres C.Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study.Clin Microbiol Infect2021;27:1015-21

[51] Henderson A,Hartel G.Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections from a large retrospective cohort study.Int J Antimicrob Agents2019;54:491-5

[52] Aldman M, Kavyani R, Kahn F, Påhlman LI. Treatment outcome with penicillin G or cloxacillin in penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective cohort study.Int J Antimicrob Agents2022;59:106567

[53] West KA,Tamura MacKay K.Eosinophilic syndromes associated with daptomycin use: re-exposure hypersensitivity pneumonitis and prior peripheral eosinophilia.Open Forum Infect Dis2022;9:ofac065 PMCID:PMC8926001

[54] Turner RB,Saedi-Kwon H.Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline.J Antimicrob Chemother2018;73:772-8

[55] Muñoz P,De Alarcon A.Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study.Medicine2015;94:e1816 PMCID:PMC4985396

[56] Ellis ME,Sandridge A,Ventura W.Fungal endocarditis: evidence in the world literature, 1965-1995.Clin Infect Dis2001;32:50-62

[57] Baddley JW,Patel M.Candida infective endocarditis.Eur J Clin Microbiol Infect Dis2008;27:519-29 PMCID:PMC2757733

[58] Arnold CJ,Bayer AS.Candida infective endocarditis: an observational cohort study with a focus on therapy.Antimicrob Agents Chemother2015;59:2365-73 PMCID:PMC4356766

[59] Cornely OA,Calandra T.ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.Clin Microbiol Infect2012;18 Suppl 7:19-37

[60] Pappas PG,Andes DR.Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America.Clin Infect Dis2016;62:e1-50 PMCID:PMC4725385

[61] Lefort A,Sendid B.Diagnosis, management and outcome of Candida endocarditis.Clin Microbiol Infect2012;18:E99-E109

[62] Giuliano S,Russo A.Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian study of endocarditis.Expert Rev Anti Infect Ther2017;15:807-18

[63] Hasse B,Keller PM.International society of cardiovascular infectious diseases guidelines for the diagnosis, treatment and prevention of disseminated mycobacterium chimaera infection following cardiac surgery with cardiopulmonary bypass.J Hosp Infect2020;104:214-35

[64] Gasch O,Espasa M,Jiménez S.Disseminated infection due to mycobacterium chimaera after aortic valve replacement.Rev Esp Cardiol2019;72:502-3

[65] Julian KG,Curley E.Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series.J Infect2020;80:197-203

[66] Forestier E,Fraisse T.Comprehensive geriatric assessment in older patients suffering from infective endocarditis. A prospective multicentric cohort study.Clin Microbiol Infect2019;25:1246-52

[67] Lacroix A,Patrat-Delon S.Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy.Med Mal Infect2014;44:327-30

[68] Baddour LM,Bayer AS.Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications.Circulation2015;132:1435-86

[69] Andrews MM.Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis.Clin Infect Dis2001;33:203-9

[70] Pericà S JM,González-Ramallo V.Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective cohort study from the GAMES cohort.Clin Infect Dis2019;69:1690-700

[71] Gil-Navarro MV,Luque-Marquez R,de Alarcon-Gonzalez A.Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.J Clin Pharm Ther2018;43:220-3

[72] Herrera-Hidalgo L,Luque-Márquez R.Ampicillin and ceftriaxone solution stability at different temperatures in outpatient parenteral antimicrobial therapy.Antimicrob Agents Chemother2020;64 PMCID:PMC7318038

[73] Dahl A,Bundgaard H.Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome.Circulation2013;127:1810-7

[74] Olaison L,Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis.Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used?.Clin Infect Dis2002;34:159-66

[75] Sullam PM,Hackbarth CJ.Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis.Antimicrob Agents Chemother1985;27:135-6 PMCID:PMC176220

[76] Yao JD,Eliopoulos GM.Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.Antimicrob Agents Chemother1990;34:827-30 PMCID:PMC171700

[77] Nicolau DP,Nightingale CH.Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.Antimicrob Agents Chemother1996;40:55-60 PMCID:PMC163056

[78] López P,Martin MT.Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis.Antimicrob Agents Chemother2001;45:1387-93 PMCID:PMC90478

[79] Pavleas J,Daikos GL.Efficacy of teicoplanin, administered in two different regimens, in the treatment of experimental endocarditis due to Enterococcus faecalis.J Chemother2008;20:208-12

[80] De Nadaï T,Sommet A.Efficacy of teicoplanin monotherapy following initial standard therapy in Enterococcus faecalis infective endocarditis: a retrospective cohort study.Infection2019;47:463-9

[81] Escolà-Vergé L,Rodríguez-Pardo D.Teicoplanin for treating enterococcal infective endocarditis: A retrospective observational study from a referral centre in Spain.Int J Antimicrob Agents2019;53:165-70

[82] Gavaldà J,Miró JM.Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.Ann Intern Med2007;146:574-9

[83] Fernández-Hidalgo N,Gavaldà J.Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis.Clin Infect Dis2013;56:1261-8

[84] Pericàs JM,Moreno A.Outcome of enterococcus faecalis infective endocarditis according to the length of antibiotic therapy: preliminary data from a cohort of 78 patients.PLoS One2018;13:e0192387 PMCID:PMC5819798

[85] Ramos-Martínez A,Fernández-Cruz A.Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: a prospective cohort study.PLoS One2020;15:e0237011 PMCID:PMC7398509

[86] Iversen K,Gill SU.Partial oral versus intravenous antibiotic treatment of endocarditis.N Engl J Med2019;380:415-24

[87] Lemaignen A,Tattevin P.Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials.BMJ Open2020;10:e033540 PMCID:PMC7365486

[88] Tobudic S,Burgmann H.Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of vienna.Clin Infect Dis2018;67:795-8

[89] Hidalgo-Tenorio C,Plata A.DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.Ann Clin Microbiol Antimicrob2019;18:30 PMCID:PMC6800500